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Abstract
Detection of human genome copy number variation (CNV) is one of the most important analyses in diagnosing human
malignancies. Genome CNV detection in formalin-fixed and paraffin-embedded (FFPE) tissues remains challenging due to
suboptimal DNA quality and failure to use appropriate baseline controls for such tissues. Here, we report a modified method
in analyzing CNV in FFPE tissues using microarray with Affymetrix Cytoscan HD chips. Gel purification was applied to select
DNA with good quality and data of fresh frozen and FFPE tissues from healthy individuals were included as baseline controls
in our data analysis. Our analysis showed a 91% overlap between CNV detection by microarray with FFPE tissues and
chromosomal abnormality detection by karyotyping with fresh tissues on 8 cases of lymphoma samples. The CNV overlap
between matched frozen and FFPE tissues reached 93.8%. When the analyses were restricted to regions containing genes,
87.1% concordance between FFPE and fresh frozen tissues was found. The analysis was further validated by Fluorescence In
Situ Hybridization on these samples using probes specific for BRAF and CITED2. The results suggested that the modified
method using Affymetrix Cytoscan HD chip gave rise to a significant improvement over most of the previous methods in
terms of accuracy in detecting CNV in FFPE tissues. This FFPE microarray methodology may hold promise for broad
application of CNV analysis on clinical samples.
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Introduction
Genome abnormalities are the hallmark of human malignancies
[1]. These include chromosome deletion, amplification, translo-
cation, inversion and isochromosome formation. Analysis of
genome abnormality is critical in making diagnosis of human
malignancies, congenital birth defects and a variety of inheritable
diseases. Array comparative genome hybridization (aCGH) or
Affymetrix SNP array has been frequently applied to clinical
samples to examine loss of heterozygosity and to detect
amplification or deletion of genome fragments in the chromo-
somes [2–8]. The current methodologies using aCGH or
Affymetrix SNP6.0 require high quality genome DNA from fresh
frozen tissues. However, most of the samples for pathological
evaluation are formalin-fixed and paraffin-embedded (FFPE) tissue
blocks. Suboptimal and high background results are obtained
when tissues from FFPE tissue blocks are analyzed due to the
fragmenting nature of genome DNA in FFPE tissues. The low
quality of genome copy number analysis from FFPE tissues
practically precludes the application of whole genome copy
number variation (CNV) analyses in clinical setting. Thus, a new
method that can reproducibly generate high quality CNV analysis
from FFPE tissues is needed to make high throughput genome
CNV analysis applicable to clinical setting.
Lymphoma is one of the human malignancies that are
frequently associated with large number of structural genome
abnormalities. The classification and treatment of lymphomas are
based on their genotypes in the tumor cells. Thus, lymphoma is an
ideal human malignancy to investigate whether FFPE tissue is
suitable for CNV analysis using Affymetrix Cytoscan HD chip. In
this report, we describe a method that is adapted to the genomic
DNA extracted from FFPE tissues to prepare the DNA cocktail for
Affymetrix Cytoscan HD analysis. To validate this method, frozen
genome DNA samples from matched lymphoma cases were also
analyzed on Affymetrix Cytoscan HD chips. The results showed
close overlaps in CNV profiles between FFPE and matched frozen
tissues.
Materials and Methods
Tissue samples
Fresh frozen tissues of eight cases of human malignant
lymphomas, including 5 diffused large B cell lymphomas, 2
follicular lymphomas and 1 T cell non-Hodgkins lymphoma, were
obtained from clinical services. These tissues were dissected to
have at least 70% purity of tumor cells. The study was approved
by University of Pittsburgh Medical Center Quality Insurance
Committee and Institutional Review Board, and exempted from
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Table 1. Genotyping concordance between FFPE and Frozen tissues.
Case Frozen genotype FFPE genotype Karyotype
Chr Locus Copy Def Size Locus Copy Def Size
Case 1 2 2p16.1 1 Loss 0.7 MB 2p16.1 1 Loss 0.5 MB 22
2q33.2-34 2.3 Gain 7.2 MB 2q33.2-34 2.3 Gain 7.2 MB
2q35-37.3 3 Gain 24 MB 2q35 2.4 Gain 24 MB
5 5q13.2-14.3 1.3 Loss 18.4 MB 5q13.2-14.3 1.4 Loss 17 MB 25
5q21.1-22.1 1.4 Loss 12 MB 5q21.1-22.1 1.5 Loss 10.5 MB
5q33.3-35.1 1.3 Loss 12.4 MB 5q33.3-35.1 1.45 Loss 11.8 MB
7 7p14.3-14.1 1.3 Loss 6.5 MB 7p14.3-14.1 1.5 Loss 6.7 MB der(7)t(7;?)(p11.2;?)
7q11.22-22.1 4 Gain 27.8 MB 7q11.22-22.1 4 Gain 24.4 MB add(7)(q22) [8]
7q22.1-36.3 3 Gain 38.3 MB 7q22.1-36.3 3 Gain 33.5 MB der(7;16)(p10;q10)
8 8p23.3-11.21 1.3 Loss 42.6 MB 8p23.3-11.22 1.4 Loss 39.6 MB 28 [17]
10q23.1-25.1 1.3 Loss 21.7 MB 10q23.1-25.1 1.5 Loss 21.3 MB
11 11p15.3-15.1 1.5 Loss 10.1 MB 11p15.4-14.3 1.5 Loss 14.2 MB
11p14.2-11.2 2.5 Gain 22 MB 11p14.2-
11.12
2.4 Gain 23.6 MB
13 13q33.3-34 1.3 Loss 6.6 MB 13q33.3-34 1.3 Loss 6.7 MB add(13)(q34) [15]
16 16p11.2-11.1 4 Gain 0.8 MB 16p11.2-11.1 3 Gain 1.2 MB
16p11.1-q21 1.3 Loss 30.4 MB 16p11.1-
q22.1
1.5 Loss 33 MB 216
16q23.1 4 Gain 2.7 MB 16q23.1 4 Gain 2.6 MB
16q23.1-23.2 1.2 Loss 3.7 MB 16q23.1-23.2 1.2 Loss 3.7 MB
16q23.2-23.3 4 Gain 1.2 MB 16q23.2-23.3 4 Gain 1.2 MB
16q23.3-24.1 1.1 Loss 2.5 MB 16q23.3-24.1 1.1 Loss 2.5 MB
16q24.1 4 Gain 2.0 MB 16q24.1 4 Gain 2.0 MB
16q24.1-24.3 1.2 Loss 2.8 MB 16q24.1-24.3 1.2 Loss 2.8 MB
17 17p13.3-13.1 2.5 Gain 8.5 MB 17p13.3-13.1 2.5 Gain 8.7 MB 217
17p12-q11.2 3 Gain 14.5 MB 17p12-q11.2 2.7 Gain 16.7 MB
17q21.33-
25.33
2.7 Gain 31.8 MB 17q21.33-
25.32
2.7 Gain 32.2 MB
X Xp22.33-q28 2 NP 154.3 MB Xp22.33-q28 3 Gain 154.3 MB +X [6]
Case 2 1 1p36.33-
36.21
1.4 Loss 16.7 MB 1p36.33-
36.13
1.5 Loss 18.2 MB
1q21.2-q44 2.7 Gain 102 MB 1q21.2-q44 2.6 Gain 102 MB der(1)(qter.1q21::p36.3.qter)
2 2p25.3-11.2 2.8 Gain 89.1 MB 2p25.3-11.2 2.6 Gain 88.9 MB
6 6q21-27 1.2 Loss 58.9 MB 6q21-27 1.4 Loss 58.7 MB
17 17p13.3-11.2 1.3 Loss 16.9 MB 17p13.3-11.2 1.5 Loss 19.2 MB del(17)(p11.2)
17p11.2-
q25.3
2.8 Gain 59.7 MB 17p11.2-
q25.3
2.7 Gain 60.3 MB i(17)(q10)
18 18p11.32-
q21.33
2.9 Gain 60.5 MB 18p11.32-
q21.33
2.8 Gain 60.1 MB +der(18)(t(14;18)(q32;q21) [4]
22 22q11.22 1 Loss 0.9 MB 22q11.22 1 Loss 1.0 MB
X Xp22.33-q28 3 Gain 156 MB Xp22.33-q28 3 Gain 156 MB +X
Case 3 1 1q24.3-42.11 2.9 Gain 55.1 MB 1q24.3-42.11 2.7 Gain 52 MB +1, der (1)
5 5p15.33-
q35.3
2.6 Gain 180.6 MB 5p15.33-
q35.3
2.6 Gain 180.6 MB 5
8 8p23.3-21.3 1.4 Loss 22.8 MB 8p23.3-21.3 1.4 Loss 22.3 MB del(8)(p21p23)
9 9p24.1-23 2.5 Gain 4.7 MB 9p24.2-23 2.4 Gain 7.1 MB add(9)(p22)
10 10p15.3 1.4 Loss 0.8 MB 10p15.3 1.5 Loss 0.8 MB dic(1;10)(10qter.10p15::1p13.1q25::1q21.1q32::1q25.1qter)
10p15.1-
11.21
2.5 Gain 31.6 MB 10p15.1-
11.21
2.5 Gain 31 MB
14 14q32.33 1 Loss 0.7 MB q32.33 1 Loss 1.0 MB add(14)(q32)
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Table 1. Cont.
Case Frozen genotype FFPE genotype Karyotype
Chr Locus Copy Def Size Locus Copy Def Size
18 18p11.32-
q11.2
3 Gain 22 MB 18p11.32-
q11.2
3 Gain 22 MB 18
18q11.2-23 4 Gain 55 MB 18q11.2-23 4 Gain 55 MB
19 19q13.2-
13.43
2.7 Gain 18.1 MB 19q13.2-
13.43
2.6 Gain 19.4 MB
X Xp22.33-q28 3 Gain 156 MB Xp22.33-q28 3 Gain 156 MB +X
Case 4 1 1p31.1 1.2 Loss 13.7 MB 1p31.1 1.4 Loss 13.2 MB 78–79,inc[cp5]*
1q23.3-32.1 2.3 Gain 31.4 MB 1q23.3-32.1 2.3 Gain 29.5 MB
1q42.2-44 1.2 Loss 17.2 MB 1q42.2-43 1.5 Loss 10 MB
2 2p25.3-24.3 2.7 Gain 13.3 MB 2p25.3-24.3 2.3 Gain 14.3 MB
2p24.3-16.3 1.5 Loss 34 MB 2p24.3-16.3 1.6 Loss 34.1 MB
3 3p26.3-
q13.13
1.6 Loss 108.1 MB 3p25.1-12.2 1.7 Loss 66.2 MB
4 4p16.3-q24 1.6 Loss 106.6 MB 4p16.3-q24 1.6 Loss 104.6 MB
4q25-34.1 2.7 Gain 64.7 MB 4q25-34.1 2.5 Gain 65.5 MB
4q34.3-35.2 2.6 Gain 7.4 MB 4q34.3-35.2 2.5 Gain 9.3 MB
5 5p15.33-
15.31
2.6 Gain 8.7 MB 5p15.33 3 Gain 0.7 MB
5q15-22 1.5 Loss 54.6 MB 5q23.3-33.1 1.6 Loss 22.5 MB
7 7p22.3-21.1 1.1 Loss 17.8 MB 7p22.3-21.1 1.4 Loss 17.3 MB
7q11.22-36.3 3 Gain 93.5 MB 7q11.22-36.3 2.8 Gain 93.6 MB
8 8p23.3-12 1.6 Loss 32.9 MB 8p23.3-12 1.6 Loss 30.9 MB
9 9p23.1-22.3 0.8 Loss 8.5 MB 9p23.1-22.3 1.2 Loss 8.1 MB
9p21.3-21.1 0.7 Loss 7 MB 9p21.3-21.1 1 Loss 6.9 MB
9p21.1 0.8 Loss 1 MB 9p21.1 1.3 Loss 1 MB
9p13.3 1 Loss 1.3 MB 9p13.3 1 Loss 1.3 MB
9p13.3-
q21.33
0.9 Loss 54.9 MB 9p13.3-
q21.33
1.3 Loss 53.2 MB
9q22.2-22.31 0.7 Loss 2.5 MB 9q22.2-22.31 1 Loss 2.4 MB
9q22.31-
22.33
1.2 Loss 4.4 MB 9q22.31-
22.33
ND NA NA
9q31.1-31.2 0.8 Loss 6.3 MB 9q31.1-31.2 1.1 Loss 5.6 MB
9q32-34.11 1 Loss 15.1 MB 9q32-34.11 1.3 Loss 17 MB
10 10p15.3-12.1 3 Gain 28.1 MB 10p15.3-12.1 2.8 Gain 28.4 MB
10p11.22 0.3 Loss 2.6 MB 10p11.22 0.7 Loss 3.6 MB
11 11q13.1-13,4 1.6 Loss 8.7 MB 11q13.1-13,4 1.7 Loss 7 MB
13 13q12.11-34 1.2 Loss 96.7 MB 13q12.11-34 1.3 Loss 96.7 MB
14 14p11.2 0.3 Loss 0.5 MB 14p11.2 0.7 Loss 0.6 MB
14q32.32 0.7 Loss 0.6 MB 14q32.32 1.2 Loss 0.6 MB
17 17p13.3-13.2 1.2 Loss 5.9 MB 17p13.3-13.2 1.5 Loss 5.8 MB
17p13.2-13.1 3 Gain 1.7 MB 17p13.2-13.1 3 Gain 0.9 MB
17p13.1-11.2 1.2 Loss 14.4 MB 17p13.1-11.2 1.3 Loss 13.4 MB
17q11.1-25.3 3.2 Gain 55.7 MB 17q11.1-25.3 2.9 Gain 54.2 MB
20 20q11.22-
13.33
3.2 Gain 30.4 MB 20q11.22-
13.33
2.7 Gain 31.1 MB
21 21q11.2-22.3 1.5 Loss 33.1 MB 21q21.2-22.3 1.7 Loss 23 MB
Case 5 10 10q22.3-
24.32
1.4 Loss 21.7 MB 10q22.3-
24.32
1.5 Loss 22.3 MB del(10)(q24q26)
13 13q14.13-
22.1
1.5 Loss 28.4 MB 13q14.13-
22.1
1.5 Loss 27.4 MB de(13)(q14q22)
Case 6 1 1p11.2-q21.2 2.6 Gain 27.4 MB 1p11.2-q21.2 2.5 Gain 33.3 MB
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Table 1. Cont.
Case Frozen genotype FFPE genotype Karyotype
Chr Locus Copy Def Size Locus Copy Def Size
4 4p16.3-q36.2 1.4 Loss 190.9 MB 4p16.3-q36.2 1.6 Loss 188.2 MB 24
5 5p15.33-
q11.2
3.2 Gain 58.8 MB 5p15.33-
q11.2
2.5 Gain 57.5 MB +5, i(5)(p10)
6 6p25.3-21.1 3.1 Gain 45 MB 6p25.3-21.1 2.5 Gain 45.3 MB
6p12.3-q27 1.4 Loss 121 MB 6p12.3-q27 1.6 Loss 97 MB 26
7 7p22.3-14.1 2.7 Gain 41.9 MB 7p22.3-14.1 2.5 Gain 45.2 MB
13 13q31.1-34 3 Gain 35.8 MB 13q31.1-34 2.5 Gain 35.8 MB add(13)(q34)
18 18q21.11-
21.33
3.2 Gain 28.4 MB 18q21.11-
21.33
2.7 Gain 28.2 MB add18(q21)
18q21.33-23 1 Loss 17.5 MB 18q21.33-23 1.3 Loss 17.6 MB
20 20p13-
q11.23
2.6 Gain 38.1 MB 20p13-
q11.23
2.5 Gain 38.1 MB
Case 7 1 1p12-q44 2.4 Gain 128.8 MB 1p12-q44 2.4 Gain 128.2 MB +1,add(1)(p32)
2 2p25.3-16.1 1.6 Loss 58.6 MB 2p25.3-16.1 1.6 Loss 58.1 MB 22
2p16.1-14 3.5 Gain 8.7 MB 2p16.1-14 3 Gain 8.7 MB
3 3p14.1-13 3.9 Gain 7.6 MB 3p14.1-13 3.5 Gain 7.6 MB 3
3q25.2-26.1 1.7 Loss 8.3 MB 3q25.2-26.1 1.7 Loss 6.0 MB
4 4p16.3-q35.2 1.6 Loss 190.9 MB 4p16.3-q35.2 1.6 Loss 190.9 MB 24
6 6p26.3-11.2 2.4 Gain 58.3 MB 6p26.3-11.2 2.5 Gain 57.3 MB +6,i(6)(p10)
7 7p22.3-36.3 2.4 Gain 159 MB 7p22.3-36.3 2.4 Gain 159 MB 7
10 10p16.3-15.2 1.6 Loss 3.6 MB 10p16.3 1.7 Loss 1.8 MB dic(1;10)(q10;p13)
17 17p13.3-
q11.1
1.6 Loss 25.6 MB 17p13.3-
q11.1
1.6 Loss 25.9 MB
i(17)(q10)
i(17)(q10)
20 20p12.3-12.1 1.5 Loss 5.9 MB 20p12.3-12.1 1.6 Loss 5.9 MB 220
20q11.1-
13.33
1.6 Loss 33.3 MB 20q11.1-
13.33
1.6 Loss 33.1 MB
Case 8 1 1p36.33-12 1.6 Loss 96.7 MB 1p36.33-12 1.7 Loss 96.7 MB i(1)(q10)
1q12-44 2.5 Gain 102.3 MB 1q12-44 2.4 Gain 102.1 MB
2 2p25.3-25.2 1.7 Loss 6.3 MB 2p25.3-25.2 1.7 Loss 5.0 MB
2p21-13.3 2.4 Gain 22.1 MB 2p16.3-13.3 2.4 Gain 17.2 MB add(2)(p11.2)
2q23.1-37.3 2.4 Gain 44.3 MB 2q23.1-37.3 2.3 Gain 37.1 MB
3 3p26.3-12.1 1.7 Loss 86.1 MB 3p26.3-12.1 1.7 Loss 84.1 MB del(3)(p13p25)
4 4p16.3-q35.2 1.6 Loss 188.5 MB 4p16.3-q35.2 1.7 Loss 188.5 MB 24
6 6q25.2-27 2.8 Gain 17.3 MB 6q25.2-27 2.5 Gain 18.5 MB
7 7q21.11-36.3 2.5 Gain 78.3 MB 7q21.11-36.3 2.4 Gain 79.2 MB add(7)(q36)
8 8p23.3-q23.1 1.6 Loss 108.8 MB 8p23.3-
q21.11
1.7 Loss 78 MB del(8)(q13q24)
9 9p24.3-q34.3 2.5 Gain 140.8 MB 9p24.3-q34.3 2.4 Gain 140.8 MB 9
10 10p15.3-
q26.3
1.7 Loss 136.3 MB 10p15.3-
q26.3
1.7 Loss 136.3 MB 210
11 11q12.1-13.5 1.7 Loss 19.2 MB 11q12.1-13.5 ND NA NA 211
15 15q11.2-26.3 1.7 Loss 79.6 MB 15q11.2-26.3 1.7 Loss 74 MB 215
18 18p11.32-
q23
1.6 Loss 77.8 MB 18p11.31-
q23
1.7 Loss 72.3 MB 218
X Xp22.33-21.2 1.5 Loss 30.1 MB Xp22.33-21.2 ND NA NA XXX
Xp21.2-
q21.33
2.5 Gain 63 MB Xp21.2-q28 2.5 Gain 133 MB
NP-normal ploidy; ND-Not detected; NA-Not applicable; Def-copy number variation definition;
*-No analysis was reported due to low number of cells survived.
doi:10.1371/journal.pone.0092820.t001
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informed-consent. The matched FFPE tissues from the same
patients were also frozen sectioned onto slides, fixed and
dehydrated with 100% ethanol and similarly micro-dissected to
obtain tumor cells. Karyotyping analyses were performed on all
these cases to detect chromosome abnormalities.
Affymetrix CytoScan HD chip analysis of copy number
variation of tumor cells
For macrodissected frozen tissues, DNA was extracted using
QIAamp blood and tissue kit (Qiagen, Valencia, CA). Five
hundred nanograms of genome DNA were digested with Nsp1 for
2 hours at 37uC. The digested DNA was purified and ligated with
primer/adaptors at 16uC for 12–16 hours. Amplicons were
generated by performing PCR using primers provided by the
manufacturer (Affymetrix, CA) on the ligation products using the
following program: 94uC for 3 min, then 35 cycles of 94uC
30 second, 60uC for 45 sec and 65uC for 1 minute. This was
followed by extension at 68uC for 7 min. The PCR products were
then purified and digested with DNAseI for 35 min at 37uC to
fragment the amplified DNA. The fragmented DNA was then
labeled with biotinylated nucleotides through terminal deoxynu-
cleotide transferase for 4 hours at 37uC. Two hundred fifty
micrograms of fragmented DNA were hybridized with a pre-
equilibrated Affymetrix chip Cytoscan HD chip at 50uC for
18 hours. The procedures of washing and scanning of Cytos-
canHD chips followed the manuals provided by Affymetrix, Inc.
Cel files were generated from AGCC software from Affymetrix,
Inc. (Santa Clara, CA). For FFPE tissues, micro-dissected tumor
cells were treated with xylene for 12 hours. DNA was then
extracted using QiaAmp FFPE DNA extraction kit. Gel purifica-
tion of DNA sizes ranging from 200 to 1000 bp was performed.
Two hundred fifty nanograms of purified DNA was then digested
with NSP1, and similarly processed as frozen tissues.
Statistical analysis
Sixteen cel files were analyzed with Genotyping console for
quality control analysis. Samples with QC call above 80% were
admitted into the analysis. To analyze CNV, cel files were
imported into Chromosome Analysis Suite 1.2 (Affymetrix, Inc) to
generate copy number from raw intensity. For frozen tissues,
Cytoscan HD files from fresh frozen tissues of 380 healthy
individuals provided by Affymetrix were used as a baseline. For
FFPE tissues, Cytoscan HD files from FFPE tissue of 100 healthy
individuals from Affymetrix were used. Deletions or amplifications
of genomes were analyzed by first limiting to the regions with p-
value less than 0.05/total number of regions detected, i.e. family-
wise error rate (FWER) is controlled using Bonferroni’s correction
[9]. The selected regions were filtered by limiting to the regions
with at least 25 markers and 500 kb. For genome fragment gain
determination, a mean of .2.3 for autosomal chromosomes or
Figure 1. Histograms of matched FFPE and Fresh frozen samples on selected chromosomes. Top panel: FFPE and frozen histograms of
chromosome 16 of Case 1; Mid panel: FFPE and frozen histograms of chromosome 17 of Case 2; Lower panel: FFPE and frozen histograms of
chromosome 9 of Case 4. Red bar denotes deletion. Blue bar denotes amplification.
doi:10.1371/journal.pone.0092820.g001
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.1.5 for sex chromosomes of male was required, while for genome
fragment loss determination, a mean of ,1.7 for autosomal
chromosomes or ,0.5 of sex chromosomes of male was required.
Loss of heterozygosity was not analyzed due to lack of matched
normal tissues.
Fluorescence In-situ Hybridization (FISH)
Tissue slides (5 microns) were placed in 26SSC at 37uC for
30 min. Slides were then removed and dehydrated in 70% and
85% ethanol for 2 min each at room temperature, and air dried.
The probes for CITED2 and BRAF FISH analysis were obtained
from BACPAC Resource Center, Oakland, CA. The DNA from
the selected clone was extracted using Nucleobond Ax kit
(Macherey-Nagel, Easton, PA). The probe was prepared by
combining 7 ml of biotin-labeled genomic sequence containing
CITED2 or BRAF (150 Kb)/50% formamide with 1 ml of direct-
labeled CEP7 spectrum green for BRAF or CEP6 for CITED2
(Vysis, Downers Grove, IL). The probe was denatured for 5 min at
75uC. Sections of formalin-fixed tissues were denatured in 70%
formamide for 3 min, and dehydrated in 70%, 85%, and 100%
ethanol for 2 min each at room temperature. The denatured
probe was placed on the slide, cover-slipped, sealed with rubber
cement, placed in a humidified chamber and hybridized overnight
at 37uC. Coverslips were removed and the slides were washed in
26SSC/0.3% NP-40 at 72uC for 2 min. Slides were then held in
phosphate buffered saline (PBS) at room temperature in the dark
for 2 min. The biotin label was visualized by conjugation with
Avidin-spectrum orange (Zymed, San Francisco, CA), cover-
slipping and incubating in a moist chamber in the dark at 37uC for
20 min. Slides were washed 3 times for 2 min each in fresh PBS.
Slides were then air-dried in the dark and counterstained with
DAPI. Analysis was performed using a Nikon Optiphot-2 and
Quips Genetic Workstation equipped with Chroma Technology
83000 filter set with single band exitors for Texas Red/
Rhodamine, FITC and DAPI (uv 360 nm). Only individual and
well delineated cells with two hybridization signals were scored.
Overlapping cells were excluded from the analysis. Fifty to 100
cells per sample were scored to obtain an average of signals.
Karyotyping analysis
Cytogenetic analysis was performed on cell cultures of
lymphoma samples. The cell cultures were stimulated with
phytohemagglutinin (PHA) for 72 hours, and harvested and
treated briefly with a hypotonic solution. The cells were then
fixed with Carnoy fixative. GTG-banding was carried out using
standard protocols [10].
Results
Affymetrix Cytoscan HD contains 2.6 million markers covering
all RefSeq genes and 750K SNPs of human genome, and has
.99% genotype accuracy. It has been widely applied to ascertain
genome abnormalities of a variety of human diseases. However, it
is rarely applied to FFPE tissues. To evaluate the usage of
Cytoscan HD on clinical FFPE samples, eight cases of lymphoma
FFPE tissues were micro-dissected and analyzed through Affyme-
trix Cytoscan HD chips. The frozen counterparts of these cases
were similarly analyzed. Karyotype analyses were performed on all
these cases for validation purpose. As shown in Table 1, karyotype
abnormalities in 24 of 51 loci had complete matches with frozen
tissue copy number analyses. Twenty-two loci from Karyotype
analyses had significant overlapped regions detected by frozen
tissue CNV analysis. Overall, this represents 90.2% (46/51)
concordance between Karyotype and Cytoscan HD analyses. Five
loci of Karyotype analyses, however, did not concord with CNV
analysis from both frozen and FFPE tissues analyses. These
differences may result from heterogeneity of the tumor samples
that some genome abnormalities appear in only a fraction of
tumor cells.
Most of the clinical samples are in the form of formalin-fixed
and paraffin-embedded tissue blocks. The dependence of array
analysis on fresh frozen tissues significantly limits its application in
clinical setting. To investigate whether FFPE tissues are suitable
for cytoscan HD analysis, DNA from the matched FFPE tissue
samples was extracted. Similar Affymetrix Cytoscan HD analyses
were performed. Cel files of FFPE tissues from 100 normal
individuals were used as baseline to calculate the copy number of
genome fragments of these FFPE samples. CNV was determined
by p,0.05 with at least 25 markers and a minimal length of
500 Kb. As shown in Tables 1–2 and figure 1, the concordant
Table 2. CNV Overlaps between Frozen tissues and matched formalin-fixed paraffin-embedded tissues.
Case Loss by Frozen loss by FFPE Overlap Gain by Frozen Gain by FFPE Overlap
Case 1 170.4 MB 170.3 MB 91.70% 180.8 MB 177.3 MB* 92.70%
Case 2 93.4 MB 97.1 MB 95.60% 311.3 MB 311.3 MB 99.60%
Case 3 24.3 MB 24.1 MB 98.80% 523.1 MB 523.1 MB 98.60%
Case 4 614.9 MB 545 MB 82.10% 334.9 MB 327.5 MB 94.90%
Case 5 50.1 MB 49.7 MB 96.80% N/D N/D N/A
Case 6 329.4 MB 302.8 MB 91.90% 275.4 MB 283.4 MB 95.90%
Case 7 326.2 MB 321.7 MB 98.40% 362.7 MB 360.8 MB 99.60%
Case 8 829.4 MB 734.9 MB 88.70% 468.1 MB 527.9 MB 82%
N/D-Not detected; N/A-Not applicable.
*Excluding X chromosome.
doi:10.1371/journal.pone.0092820.t002
Table 3. Correlation of CNV callings between FFPE and
matched fresh frozen tissues by segment number.
CNV fresh gain fresh loss
FFPE loss 68 18
FFPE gain 13 352
P,2.2610216; Pearson correlation coefficient = 0.72.
doi:10.1371/journal.pone.0092820.t003
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rates based on CNV length between arrays from the matched
FFPE and frozen tissues ranged from 82% to over 99%. Seven of
these FFPE blocks are over 1 year old and one is 3 years. The
average concordant rate for 1 year old samples is 94.1%, while the
rate for the 3 year old sample is 92%. This suggests that the quality
of the assays is stable, and is probably not adversely affected by the
age of the fixed tissues for at least 1–3 years. When CNV calling
was limited to regions that cover at least one gene, we found that
482 genome segments were either deleted or amplified in at least
one of the 16 samples. Among these segments, 68 of 86 segments
that were determined as deletion in FFPE samples matched the
same callings from fresh frozen tissue counterparts, while 352 of
365 segments that were determined as amplification matched
those from the fresh tissues (Table 3). The results confirmed a
strong correlation between FFPE and fresh frozen tissues (87.1%,
Pearson correlation coefficient = 0.72, p,2.2610216). Interesting-
ly, when CNV results of FFPE were matched with Karyotype
studies, the results were extremely similar to those between frozen
CNV and Karyotype. There is no statistically significant difference
in terms of accuracy. In fact, a slight improvement (25/51
complete match versus 24/51 frozen) was seen due to detection of
X chromosome gain in a case that was missed in frozen tissue.
To validate the CNV analysis at individual gene level, FISH
assays were performed on all 8 cases of lymphoma using probes
specific for BRAF and CITED2. Four samples of lymphoma were
found to have gain of BRAF gene by CNV analyses in both frozen
and FFPE tissues. Each of these 4 cases was found to have similar
amplification of BRAF in the FISH assays, while the other 4 CNV
neutral samples were found to have copy number near diploid
condition in FISH. The concordant rate between the CNV calls
from FFPE or frozen samples and the FISH results from the
Figure 2. FISH validation of copy number variation detected by Cytoscan HD analysis. (A) Representative images of FISH analysis using
probes specific for BRAF (7q34, red) and centromere of chromosome 7 (green). Left, normal diploid control, right-case 4 lymphoma (BRAF amplified).
(B) Representative images of FISH analysis using probes specific for CITED2 (6q23.3, red) and centromere of chromosome 6 (green). Left, normal
diploid control, right-case 2 lymphoma (CITED2 deleted).
doi:10.1371/journal.pone.0092820.g002
Table 4. Correlation of CNV callings and FISH on BRAF and
CITED2.
Genes Cases CN by frozen tissue CN by FFPE CN by FISH
BRAF 1 3 3 2.8*
2 Unchanged Unchanged 2.1
3 Unchanged Unchanged 1.9
4 3 3 2.9*
5 Unchanged Unchanged 2.2
6 Unchanged Unchanged 1.9
7 3 2.5 2.7*
8 3 3 3.1*
CITED2 1 Unchanged Unchanged 2.1
2 1 1 1.3*
3 Unchanged Unchanged 1.9
4 Unchanged Unchanged 2
5 Unchanged Unchanged 2.2
6 1.4 Unchanged 1.6*
7 Unchanged Unchanged 1.8
8 Unchanged Unchanged 2
CN-copy number;
*-p,0.01.
doi:10.1371/journal.pone.0092820.t004
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matched samples reaches 100% (8/8, Table 4 and figure 2).
CITED2, a transcription modulator essential for glycolytic
metabolism for adult hematopoietic stem cells and potential tumor
suppressor [11,12], was found deleted in 2 cases of lymphoma by
CNV analysis in frozen tissues. On the other hand, CNV analysis
in the matched FFPE tissues suggests loss of CITED2 in only one
sample. FISH assays using a probe specific for CITED2 found loss
of one copy of CITED2 gene in both cases where deletions were
also indicated by Cytoscan HD chip analyses of frozen tissues
(Table 4 and figure 2). However, 55% (117/212) of the counted
cells in one of the cases (case 6) in the FISH assay do not contain
deletion of CITED2. The large dilution by the diploid cells in this
sample may result in a negative result in FFPE CNV analysis.
Despite the high level statistical CNV concordance between
FFPE and frozen tissues, a moderately higher level of fluctuation
was readily detected in FFPE array analysis (figure 1). The average
of copy number for genome deletion for FFPE tissues is 1.44. This
magnitude of deletion is significantly less than that from frozen
tissues (1.29, p = 6.7610211). As a result, CNV analysis from FFPE
tissues could be less sensitive. Despite this mild drawback, excellent
CNV concordance between FFPE and frozen samples was evident
in most of the CNV regions, particularly those CNV loci with
large DNA fragment abnormalities (figure 1).
Discussion
The current methodologies to detect chromosome abnormalities
include Karyotyping using Giemsa staining of chromosomes, high
throughput array analysis of single nucleotide polymorphism and
DNA copy number, and whole genome sequencing. The first two
are the most commonly used methods to determine the copy
number of genome fragments, while the last one might be highly
precise but expensive. Array genome copy number analysis offers a
high resolution alternative to Karyotyping assay. However, its
clinical application is limited due to the requirement of high
quality DNA. Most clinical specimens, however, are stored in the
form of formalin-fixed and paraffin-embedded tissue blocks. The
DNA from FFPE is highly fragmented and cross-linked. This
produces a significant challenge in using FFPE tissues for high
resolution genotyping analysis. Our method using FFPE tissues to
analyze chromosomes shows an average of concordance of 93.8%
between FFPE and fresh frozen tissues. It suggests that FFPE
Cytoscan HD analysis is readily applicable to clinical setting.
Studies using FFPE tissues to analyze copy number variation
had been peviously attempted on Affymetrix 10K and SNP6.0
chips, GenomePlex aCGH, Illumina beadArray and Agilent 244K
chips (Table 5) [13–19]. However, many of these studies lack
direct validation using other methodologies. In one study, high
noise level on CNV analysis was found in FFPE samples when
using Affymetrix 6.0 chip. Only 53% concordant rate was found
between the matched frozen and FFPE samples [15]. In another
study, only selected concordance analyses were performed on
selected regions of FISH and Agilent 244K chips using FFPE
tissues [14]. The study concluded complementary roles of between
aCGH and FISH analyses. Both analyses were performed on
FFPE tissues. Recently, a FFPE OncoScan service was developed
by Affymetrix Inc to use Molecular Inversion Probe technology to
detect CNV of oncogenic hot spots [20,21]. The signal-to-noise
ratios were reduced even using FFPE tissues more than 5 years
old. However, these studies lacked direct validation comparison
between FFPE and matched frozen tissues. Thus, the fidelity of
CNV callings was not determined. Another study using optimi-
zation of universal linkage system labeling to analyze 3 cases FFPE
and matched frozen tissues. They found a good correlation in 2
cases (Pearson correlations 0.54–0.58), but found poor correlation
in the other case [22]. To our knowledge, this is the first report
that shows high concordance in CNV analysis between FFPE and
frozen tissues using Affymetrix Cytoscan HD chip. The CNV
results from FFPE not only matched well with those from frozen
tissues, but were also largely validated by cytogenetic karyotyping
and FISH analyses. The Cytoscan HD FFPE analysis holds
promise for being widely used in solid tumor and hematological
diseases diagnosis. It may be also useful in differential diagnoses of
hereditary diseases.
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Table 5. Comparison of methods analyzing CNV using FFPE tissue.
Thompson et al Little et al Tuefferd et al Lips et al Oosting et al Soroush et al Yu et al
Platform Affymetrix GenomePlex Affymetrix Illumina Illumina/Affymetrix Agilent/Affymetrix Affymetrix
Array Type 10K aCGH SNP 6.0 BeadArray BeadArray/10K aCGH/SNP6.0 CytoscanHD
Number of
Loci
10000 5623 1.85 million 5861 5861/10000 40161/1.85 million 2.6 million
CNV FFPE vs.
Frozen
NE NE 53% NA NE NA 93.80%
CNV FFPE vs.
karyotype
NE NE NE NA NE NA 91%
FISH validation
rate
NE NE NE NA NE NA 93.80%
NE-Not examined; NA-Not applicable.
doi:10.1371/journal.pone.0092820.t005
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